In Vitro Activities of the Everninomicin SCH 27899 and Other Newer Antimicrobial Agents against Borrelia burgdorferi | Zendy

Lisa L. Dever | Zendy; Christine V. Torigian | Zendy; Alan G. Barbour | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activities of the Everninomicin SCH 27899 and Other Newer Antimicrobial Agents against Borrelia burgdorferi

Author(s) -

Lisa L. Dever,

Christine V. Torigian,

Alan G. Barbour

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.7.1773

Subject(s) - microbiology and biotechnology , antimicrobial , cefepime , quinupristin , borrelia burgdorferi , dalfopristin , biology , meropenem , linezolid , antibacterial agent , antibiotics , antibiotic resistance , bacteria , imipenem , vancomycin , immunology , staphylococcus aureus , genetics , antibody

The in vitro activity of the everninomicin antibiotic SCH 27899 against 17 isolates ofBorrelia spp. was investigated. MICs ranged from 0.06 to 0.5 μg/ml. Time-kill studies with the B31 strain ofB. burgdorferi demonstrated ≥3-log10 -unit killing after 72 h with concentrations representing four times the MIC. The in vitro activity of four other newer antimicrobial agents, meropenem, cefepime, quinupristin-dalfopristin, and linezolid, was also tested against the B31 strain. Meropenem was the most potent of the latter agents, with an MIC of 0.125 μg/ml.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research